JPWO2020139991A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020139991A5 JPWO2020139991A5 JP2021538127A JP2021538127A JPWO2020139991A5 JP WO2020139991 A5 JPWO2020139991 A5 JP WO2020139991A5 JP 2021538127 A JP2021538127 A JP 2021538127A JP 2021538127 A JP2021538127 A JP 2021538127A JP WO2020139991 A5 JPWO2020139991 A5 JP WO2020139991A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- optionally substituted
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 67
- 201000011510 cancer Diseases 0.000 claims description 67
- 150000001875 compounds Chemical class 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 18
- 125000001475 halogen functional group Chemical group 0.000 claims description 18
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 15
- 206010025323 Lymphomas Diseases 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- -1 - CN Chemical group 0.000 claims description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 206010014733 Endometrial cancer Diseases 0.000 claims description 10
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 206010027406 Mesothelioma Diseases 0.000 claims description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 201000004101 esophageal cancer Diseases 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 9
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 9
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 9
- 201000005202 lung cancer Diseases 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 claims description 6
- 101710136206 S-methyl-5'-thioadenosine phosphorylase Proteins 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 5
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 5
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 5
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 5
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 5
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims description 5
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 5
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims description 5
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 5
- 208000009018 Medullary thyroid cancer Diseases 0.000 claims description 5
- 208000000172 Medulloblastoma Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000007452 Plasmacytoma Diseases 0.000 claims description 5
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 201000000582 Retinoblastoma Diseases 0.000 claims description 5
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 5
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 206010043276 Teratoma Diseases 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 208000009956 adenocarcinoma Diseases 0.000 claims description 5
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 5
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 201000010175 gallbladder cancer Diseases 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 5
- 206010024627 liposarcoma Diseases 0.000 claims description 5
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 5
- 206010027191 meningioma Diseases 0.000 claims description 5
- 201000008968 osteosarcoma Diseases 0.000 claims description 5
- 208000016802 peripheral primitive neuroectodermal tumor Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 5
- 201000006134 tongue cancer Diseases 0.000 claims description 5
- 230000002485 urinary effect Effects 0.000 claims description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 4
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 238000000034 method Methods 0.000 description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 229940125535 MAT2A inhibitor Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023208546A JP2024015340A (ja) | 2018-12-27 | 2023-12-11 | Ｍａｔ２Ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 | |
| US62/785,519 | 2018-12-27 | ||
| PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023208546A Division JP2024015340A (ja) | 2018-12-27 | 2023-12-11 | Ｍａｔ２Ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022516883A JP2022516883A (ja) | 2022-03-03 |
| JPWO2020139991A5 true JPWO2020139991A5 (es) | 2022-11-08 |
| JP7418441B2 JP7418441B2 (ja) | 2024-01-19 |
Family
ID=69400625
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538127A Active JP7418441B2 (ja) | 2018-12-27 | 2019-12-27 | Ｍａｔ２Ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法 |
| JP2023208546A Pending JP2024015340A (ja) | 2018-12-27 | 2023-12-11 | Ｍａｔ２Ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023208546A Pending JP2024015340A (ja) | 2018-12-27 | 2023-12-11 | Ｍａｔ２Ａのアザ複素二環式阻害剤、およびがんの治療のための使用方法 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US12077534B2 (es) |
| EP (1) | EP3902803B1 (es) |
| JP (2) | JP7418441B2 (es) |
| KR (1) | KR20220051301A (es) |
| CN (1) | CN113454085B (es) |
| AR (1) | AR117544A1 (es) |
| AU (1) | AU2019416349B2 (es) |
| BR (1) | BR112021012595A2 (es) |
| CA (1) | CA3124952A1 (es) |
| CL (1) | CL2021001721A1 (es) |
| CO (1) | CO2021009879A2 (es) |
| CR (1) | CR20210410A (es) |
| DK (1) | DK3902803T3 (es) |
| EA (1) | EA202191801A1 (es) |
| ES (1) | ES2942310T3 (es) |
| FI (1) | FI3902803T3 (es) |
| GE (1) | GEP20237519B (es) |
| HR (1) | HRP20230161T1 (es) |
| HU (1) | HUE061834T2 (es) |
| IL (1) | IL284326B2 (es) |
| JO (1) | JOP20210172A1 (es) |
| LT (1) | LT3902803T (es) |
| MA (1) | MA54608B1 (es) |
| MD (1) | MD3902803T2 (es) |
| MX (1) | MX2021007829A (es) |
| PE (1) | PE20212090A1 (es) |
| PL (1) | PL3902803T3 (es) |
| PT (1) | PT3902803T (es) |
| RS (1) | RS64135B1 (es) |
| SA (1) | SA521422405B1 (es) |
| SG (1) | SG11202106637SA (es) |
| SI (1) | SI3902803T1 (es) |
| TW (1) | TWI816962B (es) |
| UA (1) | UA127525C2 (es) |
| WO (1) | WO2020139991A1 (es) |
| ZA (1) | ZA202104423B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN113166078A (zh) | 2018-12-10 | 2021-07-23 | 伊迪亚生物科学有限公司 | 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂 |
| JP2023536589A (ja) * | 2020-07-31 | 2023-08-28 | タンゴ セラピューティクス， インコーポレイテッド | Ｍｔａｐ欠損及び／またはｍｔａ蓄積癌の治療に有用なピペリジン－１－イル－ｎ－ピリジン－３－イル－２－オキソアセトアミド誘導体 |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| AR127404A1 (es) | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
| EP4448517A1 (en) * | 2021-12-17 | 2024-10-23 | Tango Therapeutics, Inc. | Crystalline form of n-(6-amino-5-methylpyridin-3-yl)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide, pharmaceutical compositions and methods of use thereof |
| WO2023116696A1 (zh) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| CN118742550A (zh) * | 2022-03-11 | 2024-10-01 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| WO2024080788A1 (ko) | 2022-10-13 | 2024-04-18 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
| WO2024183778A1 (zh) * | 2023-03-06 | 2024-09-12 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| KR100571339B1 (ko) | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| EP1317448B2 (en) | 2000-09-15 | 2011-05-04 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| US8664276B2 (en) | 2011-01-28 | 2014-03-04 | University Of Kentucky Research Foundation | Stilbene analogs and methods of treating cancer |
| WO2016064960A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| IL265115B (en) * | 2016-08-31 | 2022-07-01 | Agios Pharmaceuticals Inc | Inhibitors of metabolic processes in the cell |
| US11053196B2 (en) | 2017-05-22 | 2021-07-06 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| MA52232A (fr) * | 2018-03-30 | 2021-02-17 | Agios Pharmaceuticals Inc | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer |
| EP3902804A1 (en) * | 2018-12-27 | 2021-11-03 | Les Laboratoires Servier SAS | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| AR119046A1 (es) * | 2019-05-31 | 2021-11-17 | Agios Pharmaceuticals Inc | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer |
-
2019
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 US US17/418,442 patent/US12077534B2/en active Active
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 CA CA3124952A patent/CA3124952A1/en active Pending
- 2019-12-27 BR BR112021012595-7A patent/BR112021012595A2/pt active Search and Examination
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 IL IL284326A patent/IL284326B2/en unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en active Application Filing
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/ko unknown
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
-
2021
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-27 SA SA521422405A patent/SA521422405B1/ar unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020139991A5 (es) | ||
| CA2807620C (en) | Pharmaceutically active compounds as axl inhibitors | |
| JPWO2019191470A5 (es) | ||
| KR102166002B1 (ko) | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 | |
| AU2005335298C1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2020533280A5 (es) | ||
| JP2011511095A5 (es) | ||
| JP2008538750A5 (es) | ||
| RU2009120882A (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| TW200403223A (en) | Novel compounds | |
| CN103124730A (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| AU2003242591A1 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| HRP20230161T1 (hr) | Aza-heterobiciklički inhibitori za mat2a i postupci uporabe za liječenje raka | |
| JP2013525458A5 (es) | ||
| RU2014118677A (ru) | Ингибиторы киназ типа polo | |
| JP2009515988A5 (es) | ||
| CN110088101A (zh) | 一种含氮杂环类化合物、其制备方法、药物组合物及应用 | |
| CA2514220A1 (en) | Ep4 receptor antagonists | |
| CA2608171A1 (en) | Use of quinolinone compounds for treating drug resistant cancers | |
| CN103130792A (zh) | 一种2-氨基噻唑类化合物 | |
| JP2009512706A5 (es) | ||
| JP2014516989A5 (es) | ||
| JP2005504790A5 (es) | ||
| TWI685498B (zh) | 新穎之巨環化合物，其製備方法及含彼之藥物組合物 | |
| US10556920B2 (en) | Phosphorus-containing heterocycles and a method for making and using |